Indapta Therapeutics applies TIMING to elucidate the mechanisms of enhanced ADCC

Enhanced antibody-dependent cellular cytotoxicity (ADCC) of allogeneic g-NK cell product driven in part by faster cell migration and a higher frequency of synapse formation

EVENT ALERT

HOUSTON, Texas — November 20, 2024. Indapta Therapeutics (Houston, TX & Seattle, WA) presented data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting featuring data from the CellChorus® Time-lapse Imaging Microscopy In Nanowell Grids™ (TIMING™) platform demonstrating that the enhanced antibody-dependent cellular cytotoxicity (ADCC) of the company's allogeneic g-NK cells is driven in part by faster cell migration and a higher frequency of synapse formation with target cells compared to conventional NK cells.

Indapta’s allogeneic natural killer (NK) cell therapy platform consists of a subset of naturally occurring NK cells, which are referred to as “g minus” NK cells (g-NK cells). Indapta's IDP-023 g-NK cell therapy is undergoing a Phase 1/2 clinical trial for the treatment of patients with multiple myeloma and non-Hodgkin’s lymphoma. Indapta plans to initiate a new Phase 1b clinical trial to evaluate the safety and biological activity of IDP-023 in combination with ocrelizumab for the treatment of patients living with progressive multiple sclerosis. To generate IDP-023 cells, Indapta preferentially expands g-NK cells from healthy donors. IDP-023 has several differentiated mechanisms of killing target cells without the need for genetic engineering, including highly robust antibody-dependent cell mediated cytotoxicity (ADCC) when combined with therapeutic monoclonal antibodies.

In TIMING dynamic single-cell assays, the researchers studied conventional NK cells and g-NK cells and their respective interaction dynamics and cytotoxicity kinetics with the human multiple myeloma cell line, LP-1—with or without daratumumab, an anti-CD38 monoclonal antibody (mAb). The researchers showed that compared to conventional NK cells, g-NK cells exhibited significantly higher:

  • motility;

  • synapse formation with LP-1 target cells;

  • killing of LP-1 target cells; and

  • serial killing of LP-1 cells in the presence of the mAb.

The abstract is titled "Artificial Intelligence-Based Dynamic Single-Cell Imaging Reveals Enhanced Migration and Immune Synapse Formation by IDP-023, an Allogeneic g-NK Cell Product." The full abstract is available on the Journal for ImmunoTherapy of Cancer (JITC) web site and example videos are available at the following link:

About CellChorus

CellChorus® is the leader in applying artificial intelligence to quantify the function and performance of cells over time to improve the development and delivery of novel therapies that improve patient care. The company applies Time-lapse Imaging Microscopy In Nanowell Grids™ (TIMING™) with neural network-based detection to identify how multiple types of cells move, activate, kill, proliferate, and survive at single-cell resolution. The patent-protected platform links TIMING data with other single-cell modalities to provide a comprehensive understanding of cellular function and therapeutic potential. Please visit cellchorus.com for more information.

Company Contact:
Daniel Meyer
Chief Executive Officer
CellChorus Inc.
TIMING@cellchorus.com

SOURCE CellChorus Inc.